News

• 2026.02.10
  Release(リリース)
  Notice of Application for Marketing Approval and Launch of Emergency Contraceptive Pill "LESOERU®72"
• 2026.02.05
  Financial Results(決算資料)
  Supplemental Materials of 1Q/FY2026 Consolidated Financial Results
• 2026.02.05
  Financial Results(決算資料)
  Financial Results of 1Q/FY2026

• 2026.02.05
  Financial Results
  Supplemental Materials of 1Q/FY2026 Consolidated Financial Results
• 2026.02.05
  Financial Results
  Financial Results of 1Q/FY2026
• 2026.02.05
  Financial Results
  Notice Regarding Revision of Earnings Forecast

• 2026.02.10
  Release
  Notice of Application for Marketing Approval and Launch of Emergency Contraceptive Pill "LESOERU®72"
• 2026.02.03
  Release
  Richter and Fuji strengthen strategic collaboration
• 2026.01.30
  Release
  Notice of Licensing and Settlement Regarding Aflibercept 2mg BS (Biosimilar)

• 2025.07.25
  Product
  Initiation of Phase Ⅲ clinical trial for the Alyssa® combination tablets
• 2025.06.25
  Product
  Emergency contraceptive pill : LEVONORGESTREL tablet 1.5 mg "F" Notice of Application for Marketing Approval as Switch OTC Drug
• 2019.10.23
  Product
  Manufacturing and marketing approval succession for l'estrogel 0.06% treatment for menopausal disorders

• 2026.01.27
  Other
  FY2025 Company Research and Analysis Report (Published by FISCO Ltd.)
• 2025.11.27
  Other
  Notice of the 61th Ordinary General Meeting of Shareholders
• 2025.08.22
  Other
  Corporate Report 2025 (English version) has been published